Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
RRM1 Antibody
NCTP08096
Description: Rabbit polyclonal to human RRM1
Application: ELISA, WB, IHC
Reactivity: Human
Catalog #: NCTP08096
$380.00
1000 Items
Overview
| DESCRIPTION | |
| Species Reactivity | Human. Predicted reacts with rat, mouse. Other species not tested. |
| Isotype | IgG |
| Immunogen | Recombinant human RRM1 protein 532-745aa |
| Accession # | P23921 |
| Alternative Names | Ribonucleoside-diphosphate reductase large subunit, Ribonucleoside-diphosphate reductase subunit M1, Ribonucleotide reductase large subunit, RR1 |
| Purification | Purified by protein affinity column. |
| Formulation | Lyophilized with 1% BSA and 0.02% NaN3. |
| Size | 100µg/200µl |
| APPLICATION | |
| ELISA | 1:20,000-1:80,000 |
| Western Blot | 1:200-1:1,000 |
| Immunohistochemistry | 1:100-1:500 |
| - | For research use only. Optimal dilutions/concentrations should be determined by each laboratory for each application. |
| PREPARATION AND STORAGE | |
| Reconstitution | Reconstitute in 200µl of sterile H2O. |
| Storage | Shipped at ambient temperature. Store immediately at -20°C upon receipt. Avoid repeated freeze-thaw cycles. |
| REFERENCES | |
| - | Lee SY, Im SA, Park YH et al. Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. Eur. J. Cancer 50 (4), 698-705 (2014). |